Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial
Part of paid clinical trials in Camden, New Jersey.
- Sponsor
- M.D. Anderson Cancer Center
- Study ID
- NCT06593431
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Oligometastatic
- Pancreas Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Consolidative Radiation — RADIATIONParticipants will receive treatment through radiation therapy
Study Details
The EXPAND trial (EXtending outcomes for PAncreas cancer patients with Nominal oligometastatic Disease) is a randomized phase III trial assessing the efficacy of MDT to improve PFS and OS for patients with oligometastatic pancreatic ductal adenocarcinoma (PDAC).
Key Dates
- Start date
- Oct 23, 2024
- Status verified
- May 2026
- Primary completion
- Jun 29, 2029
- Completion
- Jun 29, 2029
Study Design
- Enrollment
- 80 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: MDT (Metastasis-Directed Therapy)Patients will be randomized 1:1 to (a) MDT or (b) systemic therapy alone (no MDT).
- Experimental: System Therapy (control)Patients will be randomized 1:1 to (a) MDT or (b) systemic therapy alone (no MDT).
Primary Outcome Measure
Safety and Adverse Events (AEs) [ Time Frame: Through study completion; an average of 1 year ]
Central Contacts
- Ethan Ludmir, MD(713) 825-3169
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Cooper Hospital University Medical Center | Camden | New Jersey | 08103 | Megan Mezera, MD Megan Mezera, MD (PRINCIPAL_INVESTIGATOR) |
| Cooper Hospital University Medical Center | Voorhees Township | New Jersey | 08043 | Megan Mezera, MD Megan Mezera, MD (PRINCIPAL_INVESTIGATOR) |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Ethan Ludmir, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Camden, NJ
Related Studies
- Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid TumorsPHASE1 · Recruiting · Bicara Therapeutics · La Jolla, California
- Pancreatic Cancer Early Detection ConsortiumRecruiting · Arbor Research Collaborative for Health · Phoenix, Arizona
- Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell ManufacturingRecruiting · A2 Biotherapeutics Inc. · Gilbert, Arizona
- A Study of MGC026 in Participants With Advanced Solid TumorsPHASE1 · Recruiting · MacroGenics · Los Angeles, California